Literature DB >> 20356595

All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study.

H A W Neil1, J Cooper, D J Betteridge, N Capps, I F W McDowell, P N Durrington, M Seed, J I Mann, S E Humphries.   

Abstract

OBJECTIVE: To examine all-cause and cardiovascular mortality in patients with severe hypertriglyceridaemia.
METHODS: 337 patients aged less than 80 years (47 with diabetes, 75 women) with a fasting triglyceride concentration on at least two occasions of >5.0mmol/l were registered by 21 lipid clinics in the United Kingdom and followed prospectively between 1980 and 2008 for 4353 person-years. The standardised mortality ratio (SMR) was calculated by comparison with the general population.
RESULTS: The mean untreated total cholesterol concentration was 9.8 (SD 3.6)mmol/l for men and 11.9 (7.2)mmol/l for women and the corresponding geometric mean triglyceride concentration was 12.6 (inter-quartile range 7.3, 21.6) and 15.7 (8.2, 29.2)mmol/l. There were 70 deaths, including 35 from CHD and 7 from stroke. The SMR for CHD was raised at 327 (95% confidence intervals 228, 455; p<0.0001) and remained elevated after excluding patients with diabetes at registration (SMR=287, 95% CI 190, 419; p<0.0001), and after excluding patients with CHD at registration (SMR=259, 95% CI 158, 400; p=0.0003). The increased SMR was most marked in younger men aged 40-59 years (SMR=544, 95% CI 304, 897; p<0.0001). The SMR for stroke for patients aged 20-79 years was raised at 262 (95% CI 105, 540; p=0.04), as was all-cause mortality at 164 (95% CI 129, 208; p<0.001).
CONCLUSION: Severe hypertriglyceridaemia is associated with a substantially increased mortality from cardiovascular disease, even in the absence of diabetes. In addition to lowering triglyceride concentrations to reduce the risk of pancreatitis, treatment should aim to reduce the overall cardiovascular risk. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20356595     DOI: 10.1016/j.atherosclerosis.2010.03.006

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Changes in Lipids and Lipoproteins after Selective LDL Apheresis (7-Year Experience).

Authors:  Genovefa Kolovou; Georgios Hatzigeorgiou; Constantinos Mihas; Nikos Gontoras; Panagiotis Litras; Dimitris Devekousos; Panagiota Kontodima; Constantina Sorontila; Helen Bilianou; Sophie Mavrogeni
Journal:  Cholesterol       Date:  2012-01-24

Review 2.  Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.

Authors:  Alexander Tenenbaum; Robert Klempfner; Enrique Z Fisman
Journal:  Cardiovasc Diabetol       Date:  2014-12-04       Impact factor: 9.951

3.  The association between triglyceride/high-density lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization.

Authors:  Ke Wan; Jianxun Zhao; Hao Huang; Qing Zhang; Xi Chen; Zhi Zeng; Li Zhang; Yucheng Chen
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

4.  Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy.

Authors:  Charles J Glueck; Naseer Khan; Muhammad Riaz; Jagjit Padda; Zia Khan; Ping Wang
Journal:  Lipids Health Dis       Date:  2012-10-30       Impact factor: 3.876

5.  PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia.

Authors:  Yuri Karpov; Yunona Khomitskaya
Journal:  Cardiovasc Diabetol       Date:  2015-08-25       Impact factor: 9.951

Review 6.  Genetics of Hypertriglyceridemia.

Authors:  Jacqueline S Dron; Robert A Hegele
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-24       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.